Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04141644
Title PhIb Study Evaluating Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC (Osi+Ipi)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Utah
Indications

lung non-small cell carcinoma

Therapies

Ipilimumab + Osimertinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.